- Home
- ARCT vs BME Comparison
ARCT vs BME Comparison
Compare ARCT & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- BME
- Stock Information
- Founded
- ARCT 2013
- BME 2005
- Country
- ARCT United States
- BME United States
- Employees
- ARCT N/A
- BME N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- BME Trusts Except Educational Religious and Charitable
- Sector
- ARCT Health Care
- BME Finance
- Exchange
- ARCT Nasdaq
- BME Nasdaq
- Market Cap
- ARCT 444.5M
- BME 495.4M
- IPO Year
- ARCT N/A
- BME N/A
- Fundamental
- Price
- ARCT $9.43
- BME $38.46
- Analyst Decision
- ARCT Strong Buy
- BME
- Analyst Count
- ARCT 7
- BME 0
- Target Price
- ARCT $57.80
- BME N/A
- AVG Volume (30 Days)
- ARCT 394.6K
- BME 34.0K
- Earning Date
- ARCT 03-06-2025
- BME 01-01-0001
- Dividend Yield
- ARCT N/A
- BME 6.26%
- EPS Growth
- ARCT N/A
- BME N/A
- EPS
- ARCT N/A
- BME 1.44
- Revenue
- ARCT $152,310,000.00
- BME N/A
- Revenue This Year
- ARCT N/A
- BME N/A
- Revenue Next Year
- ARCT $39.21
- BME N/A
- P/E Ratio
- ARCT N/A
- BME $28.37
- Revenue Growth
- ARCT N/A
- BME N/A
- 52 Week Low
- ARCT $9.41
- BME $35.53
- 52 Week High
- ARCT $45.00
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- ARCT 22.40
- BME 36.35
- Support Level
- ARCT $11.71
- BME $38.20
- Resistance Level
- ARCT $13.41
- BME $38.88
- Average True Range (ATR)
- ARCT 0.86
- BME 0.44
- MACD
- ARCT -0.30
- BME -0.00
- Stochastic Oscillator
- ARCT 0.39
- BME 33.10
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.